<DOC>
	<DOC>NCT00918749</DOC>
	<brief_summary>Randomized, multicenter, double-blind, double-dummy, active-controlled, parallel-design study in approximately 201 postmenopausal women. A subset of subjects (approximately 102) will also participate in a pharmacokinetic (PK) component of the study. Each subject will be randomized to 1 of 3 treatment regimens for 3 months.</brief_summary>
	<brief_title>Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>female, 45 to 80 years of age, in good general health postmenopausal ≥2 years, surgically or naturally body mass index less than or equal to 32 kg/m^2 at screening no use within 3 months prior, nor use for more than 1 month at any time within 6 months of: glucocorticoids, anabolic steroids, estrogens, selective estrogenreceptor modulators (SERMs), or estrogenrelated drugs, progestins, calcitonin, vitamin D supplements (&gt;1200 IU per day), calcitriol, calcidiol, or alfacalcidol at any dose, any bisphosphonate. fluoride (≥10 mg/day), strontium (≥50 mg/day), parathyroid hormone, investigational bone active agents. allergic or abnormal reactions to bisphosphonates history of cancer within 5 years, excluding squamous and basal cell carcinoma with 6 month remission positive pregnancy test no depot injection &gt;10,000 IU vitamin D in previous 9 months. no history of GI disease that requires medication, or history of Crohn's disease, ulcerative colitis, diverticular disease, polyps, or surgery that could have changed GI structure or motility. no history of frequent diarrhea or constipation that requires regular laxative use. no history of alcohol or durg abuse, hyperparathyroidism, cancer previous 5 years, major surgery within 1 month prior to screening, diabetes, uncontrolled hypertension, cardiovascular, hepatic, renal or GI disease. no active hyperthyroidism, osteomalacia, use of anticonvulsant medication, or allergic reaction to bisphosphonates</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>